Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about thyroid monitoring, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
Routine calcitonin screening is not recommended and does more harm than good in this population — the false-positive rate is high and the workup is invasive. The rodent medullary thyroid carcinoma signal that drives the labelling has not translated into a human signal, but a personal or family history of MTC or MEN2 is a genuine contraindication rather than a formality. Separately, TSH is worth having at baseline because hypothyroidism explains fatigue that people will otherwise blame on the drug.
The condition it depends on
The caveat that a nodule found incidentally still needs following up on its own merits.
The practical version
Baseline worth having: TSH, and free T4 if TSH is abnormal. Calcitonin only if there is an actual MTC or MEN2 history.
What I am not sure about
What I am trying to establish is why calcitonin screening is not recommended when the label carries a thyroid warning, because those two facts look contradictory from the outside. Practical detail welcome, however dull — the duller the better.
jason_sac26 said:Routine calcitonin screening is not recommended and does more harm than good in this population — the false-positive rate is high and the workup is…
Agreed, and site choice does not change absorption for the weekly agents, so rotating costs nothing pharmacologically.
jason_sac26 said:Routine calcitonin screening is not recommended and does more harm than good in this population — the false-positive rate is high and the workup is…
Thyroid cancer screening labs for thyroid monitoring — addressing the boxed warning concern with actual data:
Calcitonin level: 2.0 pg/mL (normal <10). Checked at baseline, month 6, and month 12. Rock stable, no upward trend.
Thyroid ultrasound: normal, no nodules at month 12.
The MTC risk from rodent studies has not been confirmed in human post-marketing data across millions of patient-years. The boxed warning is a regulatory precaution based on animal data. While monitoring is prudent, the clinical risk appears to be negligible.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemThis one has a reasonably settled answer, so here it is. Site reactions are usually technique or temperature rather than the material. Injecting straight from the fridge stings more than injecting at room temperature, alcohol that has not dried carries into the puncture and burns, and re-using the same square inch produces the lump people worry about. Rotate genuinely — different quadrant each week, not different spot in the same quadrant.
LarryQC_SD said:Agreed, and site choice does not change absorption for the weekly agents, so rotating costs nothing pharmacologically.
This matches mine closely enough to be worth saying so out loud. Posting only so the count is not one.